Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Diagnosis of papulopustular rosacea (IGA score of moderate or severe) with a minimum of 12 and maximum of 50 inflammatory lesions (papules and/or pustules) and persistent erythema with or without telangiectasia~* Free of any clinically significant disease which could interfere with the study~* Willingness to follow all study procedures~* Male or female patient at least 18 years of age~Exclusion Criteria:~* Subjects known to be non-responders to azelaic acid~* Presence of dermatoses that might interfere with the rosacea diagnosis or the evaluation of treatment results~* Ocular rosacea, phymatous rosacea~* Any condition or therapy that in the opinion of the investigator may pose a risk to the patient of interfere with any evaluation in the study~* Facial laser surgery in the 6 weeks prior to the study~* Topical or systemic use of prescription or non-prescription medications to treat rosacea~* Use of any agent other than the investigational drugs to treat rosacea during the study~* Expected use or change in dose in the 90 days prior to the study of beta-blockers, vasodilators, NSAIDs, hormonal treatment or drugs causing acneiform eruptions~* Known hypersensitivity to any ingredients of the investigational product formulation~* Alcohol or drug abuse~* Incapability of giving fully informed consent~* Subject is dependent person, i.e., a relative/family member of the investigator and/or is a member of the investigator's staff~* Participation in another clinical research study within the last 4 weeks before randomization in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelaic acid foam, 15% (BAY39-6251) (Type: EXPERIMENTAL): Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
- Vehicle foam (Type: PLACEBO_COMPARATOR): Participants received vehicle foam topically twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).